IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 3, Issue 1 (2022)
J Clinic Care Skill 2022, 3(1): 19-26 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zareei S, Nabavizadeh S H, Zareei N, Abbasi R. A Retrospective Study into Causes and Treatments of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Iranian Patients. J Clinic Care Skill 2022; 3 (1) :19-26
URL: http://jccs.yums.ac.ir/article-1-122-en.html
URL: http://jccs.yums.ac.ir/article-1-122-en.html
1- Department of Biochemistry, School of Medicine, Kharazmi University, Tehran, Iran
2- Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3- Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4- Department of Pediatric, School of Medicine, Yasuj University of Medical Science, Yasuj, Iran , abbasir86@yahoo.com
2- Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3- Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4- Department of Pediatric, School of Medicine, Yasuj University of Medical Science, Yasuj, Iran , abbasir86@yahoo.com
Abstract: (1139 Views)
Aims: Stevens-Johnson syndrome and toxic epidermal necrolysis are serious severe cutaneous adverse reactions with high mortality and morbidity induced by medications. In this cross sectional study, we investigated, suspected drugs, and potential treatments of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Methods: A cross- sectional descriptive study was conducted on 60 patients admitted with a diagnosis of Stevens-Johnson Syndrome (47 patients) or Toxic Epidermal Necrolysis (13 patients). Except for the therapeutic procedure, data related to pharmacological causes and treatment was obtained from electronic medical records. They were treated daily with either co-administration of intravenous immunoglobulin (1-2mg/kg) and corticosteroid (Prednisolone Forte 1-2mg/kg; maximum 60mg/kg) or exclusive corticosteroid.
Finding: Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis were more frequent among females (56.7%) and young people (73.4%). Sepsis was observed in 11.8% of Stevens-Johnson Syndrome patients treated with intravenous immunoglobulin and corticosteroid (mean hospitalization days 2.2±0.6) but not in those who were treated with a corticosteroid (mean hospitalization days 1.6±0.5 days), though all Stevens-Johnson Syndrome patients improved after treatment. In Toxic Epidermal Necrolysis patients, 76.9% of the them showed sepsis that received intravenous immunoglobulin and corticosteroid. The mortality rate was 5%. Antibiotics and anticonvulsant drugs were found to be the main causes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Conclusion: Either intravenous immunoglobulin and corticosteroid or corticosteroid treatments seem to be effective for Stevens-Johnson Syndrome improvement. Potential drug Causes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis included Antibiotics and anticonvulsant drugs.
Methods: A cross- sectional descriptive study was conducted on 60 patients admitted with a diagnosis of Stevens-Johnson Syndrome (47 patients) or Toxic Epidermal Necrolysis (13 patients). Except for the therapeutic procedure, data related to pharmacological causes and treatment was obtained from electronic medical records. They were treated daily with either co-administration of intravenous immunoglobulin (1-2mg/kg) and corticosteroid (Prednisolone Forte 1-2mg/kg; maximum 60mg/kg) or exclusive corticosteroid.
Finding: Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis were more frequent among females (56.7%) and young people (73.4%). Sepsis was observed in 11.8% of Stevens-Johnson Syndrome patients treated with intravenous immunoglobulin and corticosteroid (mean hospitalization days 2.2±0.6) but not in those who were treated with a corticosteroid (mean hospitalization days 1.6±0.5 days), though all Stevens-Johnson Syndrome patients improved after treatment. In Toxic Epidermal Necrolysis patients, 76.9% of the them showed sepsis that received intravenous immunoglobulin and corticosteroid. The mortality rate was 5%. Antibiotics and anticonvulsant drugs were found to be the main causes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Conclusion: Either intravenous immunoglobulin and corticosteroid or corticosteroid treatments seem to be effective for Stevens-Johnson Syndrome improvement. Potential drug Causes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis included Antibiotics and anticonvulsant drugs.
Keywords: Anticonvulsants [MeSH], Adrenal Cortex Hormones [MeSH], IVIG [MeSH], Phenobarbitals [MeSH], Lyell's Syndrome [MeSH]
Article Type: Original Research |
Subject:
Special
Received: 2021/12/20 | Accepted: 2022/02/1 | Published: 2022/03/12
Received: 2021/12/20 | Accepted: 2022/02/1 | Published: 2022/03/12
References
1. Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;18(1):121-33. [link]
2. Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bavinck JNB, Halevy S, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197-204. [DOI:10.1038/jid.2012.510] [PMID]
3. Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129(11):1221-5. [DOI:10.1016/j.amjmed.2016.03.022] [PMID]
4. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7(6):803-15. [DOI:10.1586/eci.11.66] [PMID]
5. Bulisani ACP, Sanches GD, Guimarães HP, Lopes RD, Vendrame LS, Lopes AC. Stevens-Johnson syndrome and toxical epidermal necrolysis in intensive care medicine. Rev Bras Ter Intensiv. 2006;18(3):292-7. [DOI:10.1590/S0103-507X2006000300012]
6. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349-56. [DOI:10.2217/pgs.09.162] [PMID]
7. Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011;127(3 Suppl):S74-81. [DOI:10.1016/j.jaci.2010.11.048] [PMID]
8. Prabagar MG, Choi HJ, Park JY, Loh S, Kang YS. Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute. Clin Exp Med. 2014;14(4):361-73. [DOI:10.1007/s10238-013-0255-4] [PMID]
9. Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci. 2004;9:411-20. [DOI:10.2741/1249] [PMID]
10. Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514-22. [DOI:10.1001/jamadermatol.2016.5668] [PMID] [PMCID]
11. Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985-96. [DOI:10.1172/JCI93349] [PMID] [PMCID]
12. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J-C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6.
https://doi.org/10.1001/archderm.1993.01680220104023 [DOI:10.1001/archderm.129.1.92]
13. Roujeau JC, Ghislain PD, Valleyrie-Allanore L. Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Williams HC, Bigby M, Herxheimer A, Naldi L, Rzany B, Dellavalle RP, Ran Y, Furue M, editors. Evidence-based dermatology. Hoboken, New Jersey: John Wiley & Sons; 2014. pp. 578-85. [DOI:10.1002/9781118357606.ch68]
14. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-8. [DOI:10.1038/clpt.2009.252] [PMID]
15. Devi K, George S, Criton S, Suja V, Sridevi P. Carbamazepine-The commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: A study of 7 years. Indian J Dermatol Venereol Leprol. 2005;71(5):325-8. [DOI:10.4103/0378-6323.16782] [PMID]
16. Abdulah R, Suwandiman TF, Handayani N, Destiani DP, Suwantika AA, Barliana MI, et al. Incidence, causative drugs, and economic consequences of drug-induced sJs, Ten, and sJs-Ten overlap and potential drug-drug interactions during treatment: A retrospective analysis at an indonesian referral hospital. Ther Clin Risk Manag. 2017;13:919-25. [DOI:10.2147/TCRM.S142226] [PMID] [PMCID]
17. Fritsch P. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Eur J Dermatol. 2008;18(2):216-7. [link]
18. Kim HI, Kim SW, Park GY, Kwon EG, Kim HH, Jeong JY, et al. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med. 2012;27(2):203-10. [DOI:10.3904/kjim.2012.27.2.203] [PMID] [PMCID]
19. Lihite RJ, Lahkar M, Borah A, Hazarika D, Singh S. A study on drug induced Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and SJS-TEN overlap in a tertiary care hospital of Northeast India. J Young Pharm. 2016;8(2):149-53. [DOI:10.5530/jyp.2016.2.18]
20. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: Treatment outcomes. Acta Derm Venereol. 2012;92(1):62-6. [DOI:10.2340/00015555-1169] [PMID]
21. Roongpisuthipong W, Prompongsa S, Klangjareonchai T. Retrospective analysis of corticosteroid treatment in Stevens-Johnson syndrome and/or toxic epidermal necrolysis over a period of 10 years in Vajira Hospital, Navamindradhiraj University, Bangkok. Dermatol Res Pract. 2014;2014:237821. [DOI:10.1155/2014/237821] [PMID] [PMCID]
22. Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147-76. [DOI:10.1007/s12016-017-8654-z] [PMID]
23. Gueudry J, Roujeau J-C, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2):157-62. [DOI:10.1001/archdermatol.2009.540] [PMID]
24. Van Zyl L, Carrara H, Lecuona K. Prevalence of chronic ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis. Middle East Afr J Ophthalmol. 2014;21(4):332-5. [DOI:10.4103/0974-9233.142272] [PMID] [PMCID]
25. Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients-Treatment and outcome. Allergol Int. 2016;65(1):74-81. [DOI:10.1016/j.alit.2015.09.001] [PMID]
26. Wang YH, Chen CB, Tassaneeyakul W, Saito Y, Aihara M, Choon SE, et al. The medication risk of stevens‐johnson syndrome and toxic epidermal necrolysis in asians: The major drug causality and comparison to the USA FDA Label. Clin Pharmacol Ther. 2019;105(1):112-20. [DOI:10.1002/cpt.1071] [PMID]
27. Thammakumpee J, Yongsiri S. Characteristics of toxic epidermal necrolysis and Stevens-Johnson syndrome: A 5-year retrospective study. J Med Assoc Thai. 2013;96(4):399-406. [link]
28. Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25(8):402-11. [DOI:10.1097/FPC.0000000000000153] [PMID]
29. Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau J-C, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: A pooled analysis. Pediatrics. 2009;123(2):e297-304. [DOI:10.1542/peds.2008-1923] [PMID]
30. Sethuraman G, Sharma VK, Pahwa P, Khetan P. Causative drugs and clinical outcome in Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap in children. Indian J Dermatol. 2012;57(3):199-200. [DOI:10.4103/0019-5154.96192] [PMID] [PMCID]
31. Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):389-98. [DOI:10.4103/0378-6323.110749] [PMID]
32. Singh J, Gupta KK, Dinkar A, Atam V, Mishra R. Steven-Johnson syndrome following sodium valproate monotherapy. Indian J Pharm Pharmacol. 2016;3(4):227-8. [link]
33. Nascimento S, Freitas F, Pereira D, Filipe T, Viveiros V, Costa C, et al. Stevens-Johnson syndrome induced by sodium valproate-a case report. Eur Neuropsychopharmacol. 2017;27:S645-S6. [DOI:10.1016/S0924-977X(17)31211-7]
34. Law EH, Leung M. Corticosteroids in Stevens-Johnson Syndrome/toxic epidermal necrolysis: Current evidence and implications for future research. Ann Pharmacother. 2015;49(3):335-42. [DOI:10.1177/1060028014560012] [PMID]
35. Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, et al. Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: A prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol. 2013;79(4):506-11. [DOI:10.4103/0378-6323.113080] [PMID]
36. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144-8. [DOI:10.2340/00015555-0214] [PMID]
37. Aihara M, Kano Y, Fujita H, Kambara T, Matsukura S, Katayama I, et al. Efficacy of additional i.v. immunoglobulin to steroid therapy in S tevens-J ohnson syndrome and toxic epidermal necrolysis. J Dermatol. 2015;42(8):768-77. [DOI:10.1111/1346-8138.12925] [PMID]
38. Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: A retrospective study of 82 cases. Eur J Dermatol. 2010;20(6):743-7. [link]
39. Patmanidis K, Sidiras A, Dolianitis K, Simelidis D, Solomonidis C, Gaitanis G, et al. Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient. Case Rep Dermatol Med. 2012;2012:915314. [DOI:10.1155/2012/915314] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |